9 June 2016 - NICE has published a second appraisal consultation for GSK's Nucala (mepolizumab).

Mepolizumab is not recommended within its marketing authorisation as an add-on for treating severe refractory eosinophilic asthma.

The closing date for comments is 29 June 2016. The third appraisal committee meeting will be held on 4 August 2016.

For more details, go to: https://www.nice.org.uk/guidance/indevelopment/gid-tag519/consultation/html-content-2